Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mind Over Matter Medtech (MOMM) is a London-based medical technology company specializing in the development of rapid, point-of-care diagnostic solutions for traumatic brain injury (TBI). The company's flagship platform utilizes advanced biosensing technology to detect blood-based biomarkers associated with brain trauma, such as GFAP and H-FABP, providing objective results within minutes. By enabling early and accurate diagnosis at the site of injury, MOMM seeks to improve patient outcomes and streamline triage in emergency departments and sports medicine settings. The technology is designed to be portable, cost-effective, and significantly more sensitive than traditional symptom-based assessments. MOMM's mission is to provide clinicians with actionable data during the critical 'golden hour' following a head injury.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mind Over Matter Medtech.